The Short Version
Recent studies do support red-blood-cell-based systems as promising anticancer drug carriers. Multiple peer-reviewed papers show improved delivery and, in some animal tumor models, better efficacy or lower toxicity. The key caveat is that most of this evidence is preclinical, so the claim should not be read as proof of established effectiveness in human cancer care.